Dietary Insights and Nutrition Experiences in Adults on GLP-1 Therapy - A Study on Diet Quality Changes in Adults on GLP-1 Therapy

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversity of South Carolina

About this trial

The DINE-GLP1 study aims to understand how people on GLP-1 therapy change their eating habits and what kind of dietary support they need. As more people use GLP-1 medications, there's not much guidance on what they should eat, mostly just focusing on managing symptoms and cutting calories. Since these medications reduce food intake, it's important to ensure the diet is nutritious even with fewer calories to help with long-term weight control and health. Most research has looked at how the body responds to the medication and whether patients take it as prescribed, but not much is known about what patients actually experience, what they think they need, or how they could use additional support. Understanding patients' views can help create better lasting solutions. Note that this study does not provide free GLP-1 medication.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Adults aged 18 and older

Recently has been prescribed GLP-1 therapy for the treatment of obesity or T2DM but have not yet initiated the medication

Has regular access to a smartphone and internet to complete short surveys and food recalls online

Willing to sign informed consent.

Disqualifiers

Already began the GLP-1 medication

Have medical concerns making participation unsafe

Trial population

The recruitment will be conducted at the Prisma Health Weight Management Institute in Greenville, South Carolina, with support from the on-site research team. A total of 50 patients will be enrolled. Eligible individuals will be adults aged 18 years or older who have recently been prescribed GLP-1 therapy for the treatment of obesity or T2DM but have not yet initiated the medication.

Trial design

Design model

Cohort

Time perspective

Cross-sectional

Treatments tested in this trial

  • GLP-1 Therapy

    Drug

    Exposure to GLP-1 Therapy for obesity or T2DM management.

Treatment groups

50 Participants
are divided into 1 treatment group
Group A: GLP-1 Therapy1 intervention

Trial outcomes

Primary outcomes

1

Change in Healthy Eating Index

The Healthy Eating Index (HEI) is a scoring metric developed by the U.S. Department of Agriculture (USDA) and the NCI to assess how well a person's diet conforms to the Dietary Guidelines for Americans. It evaluates the consumption of 13 dietary components, including both adequacy (foods to increase) and moderation (foods to decrease). The scores range from 0 to 100. An ideal overall HEI score of 100 reflects that the set of foods aligns with key dietary recommendations and dietary patterns published in the Dietary Guidelines.

Time frame
Baseline and 12-weeks

Secondary outcomes

1

Change in Body Weight

Change from Baseline in Body Weight at 12-weeks

Time frame
Baseline and 12 weeks

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

University of South Carolina

Lead sponsor

Prisma Health-Upstate

Collaborator